Hemispherx Biopharma to Present at the New York Society of Security Analysts 9th Annual Healthcare Industry Conference; New Influenza Treatment / Prevention Initiatives Introduced.

PHILADELPHIA -- Hemispherx Biopharma, Inc. (AMEX: HEB) announced that Dr. William A. Carter, Chairman & CEO, will present at the New York Society of Security Analysts (NYSSA) 9th Annual Healthcare Industry Conference Thursday, December 15th at 11:20am EST.

In the presentation, Dr. Carter will be reviewing the various achievements and progress the Company has made throughout the year. The Company has recently entered into clinical trials with their experimental products Ampligen, Alferon N, Alferon LDO (Low Dose Oral) against Avian Influenza as a stand-alone antivirals and vaccine adjuvant to expand available supplies. These global based trials will be highlighted in the presentation.

The NYSSA 9th Annual Healthcare Industry Conference will be held at The Harvard Club, 27 West 44th Street in New York City. For additional information about attending this conference, please call 212-541-4530 or on-line at: http://www.nyssa.org/

This presentation will be audio webcast live and can be accessed on Hemispherx's website at http://www.hemispherx.net .

An archived version will be available for 30 days after the live presentation and can be accessed at the same location.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Hemispherx's flagship products include Alferon and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(R). Alferon is commercially approved for a category of STD infection, and Ampligen(R) and Oragens(R) represent experimental nucleic acids being developed for globally important viral diseases and disorders of the immune system including HPV, HIV, CFS, Hepatitis and influenza. Alferon LDO(TM) is a new experimental drug delivery platform for the Company's commercial product Alferon N(R). Hemispherx's platform technology includes large and small agent components for potential treatment of various viral infections. Hemispherx has in excess of 100 patents comprising its core intellectual property estate covering various forms of double-stranded (ds) RNA and their fields of therapeutic application, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products in New Brunswick, New Jersey. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen, Alferon LDO and Oragens(R)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.